Skip to main content

Remote Job Finders (RJF)

Sarepta CEO Doug Ingram To Step Down as Muscular Dystrophy Mission Hits Home

When Ingram became Sarepta Therapeutics’ CEO in 2017, he didn’t have a connection to muscular dystrophy, but he has developed a fierce passion for the therapeutic area. He will step aside from his role to dedicate more time to his family.

After Sarepta’s Annus Horribilis, Elevidys Sales Expected To Continue Downward Spiral

After a rocky 2025, Sarepta Therapeutics’ executives admit they have work to do to bring patients back into the fold as sales of Duchenne muscular dystrophy gene therapy Elevidys continue to decline.

Boehringer Seeks To Rebalance Immunity With Sitryx Collab Potentially Worth $500M+

While Boehringer Ingelheim hasn’t yet revealed what diseases it will go after, Sitryx’s oral drug candidate could potentially be disease-modifying for a variety of autoimmune and inflammatory conditions.

The Right Fit: Contract Work Finds Increasing Favor Among Employers, Professionals

Contract work opportunities have grown year over year, and recent reports show more people are in this type of role, according to BioSpace data. Three biopharma professionals share why they’ve become contractors and discuss the pros and cons.

AI Tips and Prompts That Can Take Your Job Search to the Next Level

While you should never rely solely on AI tools when applying for jobs, they can greatly benefit the application process. Recruiting expert Bryan Blair discusses how using large language models can set you apart from the competition and includes a prompt framework to get you started.

Novo Leans Into Oral Route With Weight Loss Partnership Worth up to $2.1B

After its next-generation obesity asset CagriSema lost a head-to-head matchup with Eli Lilly’s Zepbound, Novo Nordisk is throwing more money into the obesity space, striking a deal with Vivtex to advance novel weight loss pills.
Scroll to top